-
Product Insights
New![]()
Net Present Value Model: Tenaya Therapeutics Inc’s TN-201
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Tenaya Therapeutics Inc’s TN-301
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TN-301 in Diastolic Heart Failure (HFpEF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TN-301 in Diastolic Heart Failure (HFpEF) Drug Details: TN-301 (TYA-11631) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TN-201 in Hypertrophic Cardiomyopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TN-201 in Hypertrophic Cardiomyopathy Drug Details: TN-201 is under development for the treatment of cardiomyopathy....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TN-301 in Diastolic Heart Failure
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TN-301 in Diastolic Heart FailureDrug Details:TN-301 (TYA-11631) is under development for the treatment of heart failure...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TST-005 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TST-005 in Esophageal Cancer Drug Details:TST-005 is under development for the treatment of solid tumors including...
-
Company Profile
![]()
Tenaya Therapeutics Inc – Company Profile
Tenaya Therapeutics Inc (Tenaya Therapeutics) is a biopharmaceutical company. It develops novel therapies for the treatment of heart diseases. The company develops treatments through its product platforms that include cellular regeneration, gene therapy and precision medicine. Its cellular regeneration platform uses novel adeno-associated virus (AAV) vectors to deliver proprietary transcription factors that can drive in vivo reprogramming of resident cardiac fibroblasts into cardiomyocytes. The company’s platform uses isogenic iPSC-derived cardiomyocytes as human disease models to identify and validate new heart...
Add to Basket -
Sector Analysis
![]()
Sportswear Market Size and Trend Analysis by Category (Apparel, Footwear, Accessories), Segments (Type, Gender, Positioning, Activity), Retail Channel, Region, Key Brands, Consumer Attitudes to 2026
Accessing in-depth insights from the ‘Sportswear Market’ report will help you: Understand the key market drivers, trends, and inhibitors to help pinpoint specific opportunities to make sales and business strategies within the sportswear market. Identify your market players' capabilities (strengths and weaknesses) to take a competitive advantage. Identify what makes the leading sportswear players successful, with insights into how those strategies could be integrated within your own business. Learn about the geographical differences within the sportswear market, and which are the key countries...
-
Product Insights
![]()
Net Present Value Model: TN-401
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TN-401 Drug Details TN-401 is under...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – TN-301
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TN-301 Drug Details TN-301 (TYA-11631) is under development for the treatment of heart failure...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.